Education
About Us
Working with TipRanks
Follow Us
Maze Therapeutics, Inc. (MAZE)
NASDAQ:MAZE
| Dec 24 | Dec 23 | Dec 22 | |
|---|---|---|---|
| Income Statement | |||
| Total Revenue | $ 167.50M | $ 0.00 | $ 0.00 |
| Gross Profit | $ 167.50M | $ 0.00 | $ 0.00 |
| Operating Income | $ 57.59M | $ -98.55M | $ -111.03M |
| EBITDA | $ 60.88M | $ -94.46M | $ -107.21M |
| Net Income | $ 52.23M | $ -100.42M | $ -114.94M |
| Balance Sheet | |||
| Cash & Short-Term Investments | $ 196.81M | $ 29.16M | $ 99.92M |
| Total Assets | $ 240.54M | $ 71.50M | $ 149.96M |
| Total Debt | $ 26.63M | $ 49.62M | $ 32.05M |
| Net Debt | $ -170.18M | $ 20.46M | $ -67.86M |
| Total Liabilities | $ 43.64M | $ 61.45M | $ 48.51M |
| Stockholders' Equity | $ 196.90M | $ 10.05M | $ 101.44M |
| Cash Flow | |||
| Free Cash Flow | $ 74.81M | $ -87.27M | $ -101.17M |
| Operating Cash Flow | $ 75.95M | $ -86.83M | $ -99.20M |
| Investing Cash Flow | $ -1.15M | $ -441.00K | $ -3.17M |
| Financing Cash Flow | $ 92.85M | $ 16.39M | $ 1.73M |